We claim:

1. A liquid pharmaceutical formulation comprising an effective amount of an antibody or antigen binding portion thereof directed to TNFα in a buffer system with a pH between 4 to 8, a surfactant, a tonicity agent and a stabilizer selected from amino acids and cyclodextrines wherein the antibody is Adalimumab or its antigen binding portion.

~~2. The formulation as claimed in claim 1, wherein the antibody or antigen binding portion thereof is polyclonal or monoclonal or recombinant antibodies or single chain antibodies or hybrid antibodies or chimeric antibodies or humanized antibodies or fragments thereof or isolated human antibodies or antibody portions thereof.~~

3. The formulation as claimed in claim 1, wherein the concentration of antibody is between 1 mg / mL to 160 mg / mL preferably 1 mg / mL to 100 mg / mL.

4. The formulation as claimed in claim 3, wherein the concentration of antibody is 50 mg / mL.

5. The formulation as claimed in claim 1, wherein the pH of the formulation is between pH 5.0 and pH 5.5, preferably at pH 5.2.

6. The formulation as claimed in claim 1, wherein the buffer system is selected from histidine-buffers, citrate-buffers, succinate-buffers, acetate-buffers, phosphate-buffers, phosphate buffered saline, citrate and phosphate buffer, tromethamine buffers and suitable mixtures thereof.

7. The formulation as claimed in claim 6, wherein the buffer system is a succinate- buffer or acetate-buffer or histidine buffer or suitable mixture thereof.

8. The formulation as claimed in claim 7, wherein the buffer system is a succinate-buffer.

9. The formulation as claimed in claim 1, wherein the buffer is in the concentration of ImM to about 100 mM, preferably 5 mM to 50 mM, more preferably 10 mM to 20 mM.

10. The formulation as claimed in claim 1, wherein the amino acid is selected from arginine, glycine, lysine, histidine, glutamic acid, aspartic acid, isoleucine, leucine, alanine, phenylalanine, tyrosine, tryptophane, methionine, serine, proline, cysteine / cystine and suitable combination thereof.

~~11~~10. The formulation as claimed in claim ~~10~~9, wherein the stabilizer is arginine alone or in combination with other suitable amino acids.

~~12~~11. The formulation as claimed in claim 1, wherein the cyclodextrin is selected from a-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, their hydroxypropylated, hydroxyethylated, ethylated and methylated derivatives thereof, Sulfobutyl ether beta-cyclodextrin (SBE-beta-CD), a branched cyclodextrins, cyclodextrin polymers and suitable mixture thereof.

~~13~~12. The formulation as claimed in claim ~~11~~12, wherein stabilizer is hydroxypropylated cyclo beta-dextrin (HP-β-CD).

~~14~~13. The formulation as claimed in claim 1, comprising additional stabilizers selected from sugars and polyols, including their suitable combination.

~~15~~14. The formulation as claimed in claim ~~14~~13, wherein the sugar is selected from glucose, fructose, galactose, mannose, sorbose, ribose, deoxyribose, sucrose, trehalose, lactose, maltose, raffinose and suitable mixtures thereof preferably trehalose or raffinose.

~~16~~15. The formulation as claimed in claim ~~15~~13, wherein the polybl is selected from mannitol, sorbitol, dextran, glycerol, arabitol, propylene glycol, polyethylene glycol and suitable combinations thereof.

~~17~~16. The formulation as claimed in claim ~~16~~15, wherein the stabilizer is sorbitol.

~~18~~17. The formulation as claimed in claim ~~10~~9, wherein the amino acid is present in the concentration of 1% to 10%.

~~19~~18. The formulation as claimed in ~~12~~11, wherein the cyclodextrin is in the concentration of 0.2% to 10 %.

~~20~~19. The formulation as claimed in claim 1 which further comprises ~~suitable~~ excipients selected from surfactants, tonicity agent and suitable combination thereof.

~~21~~20. The formulation as claimed in claim ~~20~~19, wherein the surfactant is selected from polyoxyethylensorbitan fatty acid esters (Tween), polyoxyethylene alkyl ethers, alkylphenylpolyoxyethylene ethers, polyoxyethylene-polyoxypropylene copolymer and sodium dodecyl sulphate (SDS).

~~22~~21. The formulation as claimed in claim ~~21~~20, wherein the surfactant is selected from polysorbate 20 or polysorbate 80.

~~23~~22. The formulation as claimed in claim ~~22~~21, wherein the surfactant is 0.001 % to about 1 %.

2423. The formulation as claimed in claim 2322, wherein the tonicity agent is sodium chloride or potassium chloride.

2524. The formulation as claimed in claim 2019, wherein the tonicity agent is present in amount about 10 mM to about 150 mM,

2625. A formulation as claimed in claim 1 comprising

a) 1 - 160 mg / mL of antibody,

b) 1-10% stabilizer

c) A buffer system with a pH of 4 to 8.

2726. The formulation as claimed in claim 2625, wherein the stabilizer is selected from sorbitol, raffinose, trehalose, arginine, lysine, hydroxypropylated cyclo beta- dextrin (HP-β-CD) and combination thereof.

2827. The formulation as claimed in claim 2625, wherein the buffer system is a succinate or acetate or histidine buffer system.

~~29. The formulation as claimed in claim 26, wherein the antibody is directed to TNFα.~~

~~30. The formulation as claimed in claim 26, wherein the antibody is Adalimumab or antigen binding portion thereof.~~

3128. The formulation as claimed in claim 26-25 wherein the antibody concentration is 50 mg / mL.

3229. The formulation as claimed in claim 26-25 which further comprises a surfactant and/or tonicity agent.

3330. The formulation as claimed in claim 2726, wherein the surfactant is polysorbate 80 and the tonicity agent is sodium chloride.

3431. A formulation claimed in claim 1 comprising

a) 50 mg / mL of antibody,

b) 10 mg / mL sorbitol,

c) 5 mg / mL arginine

d) 0.1 mg / mL polysorbate 80

e) 10 mM Succinate buffer of pH of 5.2.

3532. A lyophilized formulation comprising the composition as claimed in claim 1-3431.

3633. The formulation of claim 35-32 wherein the lyophilized powder is reconstituted with water.

3734. The formulation as claimed in claim 1 is suitable for parenteral administration.

~~38~~35. Use of a~~The~~ formulation of claim 1 in the manufacture of a medicament for treating ~~which is administered to~~ a patient suffering from the disorder in which activity of TNFα is detrimental.